]>
IRCT20081208001497N10 IRCT 2022-02-26 Esfahan University of Medical Sciences Evaluation of the effect of licorice as an adjunctive therapy for patients with Covid-19 admitted to the intensive care unit Evaluation of the effect of licorice as an adjunct treatment for patients with Covid-19 admitted to the intensive care unit: A randomized, placebo-controlled, double-blind clinical trial 2022-03-05 anticipated 60 Complete https://irct.ir/trial/61716 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The samples will be randomized by random blocking method with blocks of 4 which generated by Random Allocation software version 2. Blocking and allocation sequence for concealment will be done by the person not involved in the research (Allocation Concealment). The sample allocation ratio will be (1: 1 Allocation) and will be divided into two groups of drug recipients and placebo (Assignment). Drugs will then be given to patients based on the blocks obtained and in the order of allocation, Blinding description: This study will be performed as double-blind. The drug and placebo packing package and code allocation is done by the researcher involved in the research and then provided to the main researcher. In this way, the physician and patients will not know the contents of the packages and the type of codes and will not know which of the two control or test groups it belongs to. 3 Covid-19. Intervention 1: Intervention group: Eligible patients receive 760 mg / day (equivalent to two tablets) d-reGliss (Iran Darok) for five days. Patients will receive other routine Covid-19 treatments according to the hospital protocol. Intervention 2: Control group: They receive the usual treatments along with placebo pills. This pill is prepared by Iran Darok Pharmaceutical Company and contains exponents such as lactose and magnesium stearate without active ingredient. Yes - There is a plan to make this available What will be shared: Published article When: One year To whom: All people Conditions: No condition Where to obtain: Scientific responded of the study How to obtain: Scientific responded of the study Comments:
public Sarah Mousavi
Hezar Jerib avenue, Isfahan University of Medical Sciences, Faculty of pharmacy, Clinical Pharmacy D
Isfahan Iran (Islamic Republic of) 81746 73461 +98 31 3792 7072 s.mousavi@pharm.mui.ac.ir Esfahan University of Medical Sciences scientific Sarah Mousavi
Hezar Jerib avenue, Isfahan University of Medical Sciences, Faculty of pharmacy, Clinical Pharmacy D
Isfahan Iran (Islamic Republic of) 81746 73461 +98 31 3792 7072 s.mousavi@pharm.mui.ac.ir Esfahan University of Medical Sciences Iran (Islamic Republic of) Covid-19 diagnosis based on PCR test Hospitalized in the intensive care unit and under mechanical ventilation 18 years no limit Both 1. Patients with high blood pressure (<90/140) Patients with congestive heart failure Patients with severe liver, kidney and thyroid disease Concomitant use of warfarin, SSRI, MAOI, diuretics, antiarrhythmic drugs Treatment with antiviral drugs one month before entering the study Allergy to licorice Pregnancy and lactation Dissatisfaction of the patient or his legal guardian Infected with Covid-19 for at least 20 days prior to enrollment U07.1 U07.1 COVID-19, virus identified Treatment - Drugs Placebo Intervention group: Eligible patients receive 760 mg / day (equivalent to two tablets) d-reGliss (Iran Darok) for five days. Patients will receive other routine Covid-19 treatments according to the hospital protocol. Control group: They receive the usual treatments along with placebo pills. This pill is prepared by Iran Darok Pharmaceutical Company and contains exponents such as lactose and magnesium stearate without active ingredient. Average time out of intensive care unit. Timepoint: After discharge. Method of measurement: Number of hospitalization days. Speed of recovery of Covid-19 clinical signs. Timepoint: The first and fourteenth day. Method of measurement: Percentage of improvement in symptoms. Duration of hospitalization in the intensive care unit. Timepoint: After discharge or death. Method of measurement: Number of days of hospitalization. Duration of mechanical ventilation. Timepoint: During hospitalization. Method of measurement: Number of days under mechanical ventilation. Esfahan University of Medical Sciences Approved 2022-02-20 Ethics Committee of Isfahan University of Medical Sciences Isfahan University of Medical Sciences, P.O. Box 319, Hezar-Jerib Ave. Isfahan Isfehan Iran (Islamic Republic of)